Upgrading acquired Stelis unit to triple Syngene's biologics capacity by H2

The company plans to expand research and manufacturing facilities, allocates Rs 500 cr capex for FY25

This report has been updated

Biocon subsidiary Syngene International’s acquisition of Unit 3, a biologics manufacturing facility, from Stelis Biopharma is expected to boost its biologics production capacity three times , a senior company official said. Originally a vaccine production facility, Unit 3 is being repurposed to manufacture monoclonal antibodies.

Syngene acquired the multi-modal biologics manufacturing facility from Stelis Biopharma Ltd on July 4, 2023, for Rs 702 crore, and completed the deal around December 2023. 

“Initially a vaccine production facility, it's been adapted meticulously over the past five to six months to meet the stringent requirements for antibody production.